262
Views
14
CrossRef citations to date
0
Altmetric
Original Article

Clinical features and pregnancy outcome in antiphospholipid syndrome patients with history of severe pregnancy complications

, , , , , , , , & show all
Pages 215-218 | Received 09 May 2014, Accepted 04 Jul 2014, Published online: 22 Aug 2014
 

Abstract

Objective. To clarify the clinical significance of antiphospholipid antibody (aPL) profile in patients with obstetric antiphospholipid syndrome (APS).

Methods. Clinical records of 13 pregnant patients (15 pregnancies) with obstetrical APS were reviewed over 10 years. Patients who met the Sapporo Criteria fully were studied, whereas those with only early pregnancy loss were excluded. In addition to classical aPL: lupus anticoagulant (LA), anticardiolipin antibody (aCL), and anti-β2-glycoprotein I (aβ2GPI); phosphatidylserine-dependent anti-prothrombin antibody (aPS/PT) and kininogen-dependent anti-phosphatidylethanolamine antibody (aPE) were also examined in each case.

Results. Cases were divided into two groups according to patient response to standard treatment: good and poor outcome groups. All cases with poor outcome presented LA, with IgG aβ2GPI and IgG aPS/PT were also frequently observed. IgG aPE did not correlate with pregnancy outcome.

Conclusion. aPL profile may predict pregnancy outcome in patients with this subset of obstetric APS.

Acknowledgment

We would like to thank Dr. Julian Tang from the Department of Education for Clinical Research, National Center for Child Health and Development, for proofreading and editing this manuscript.

Conflicts of interest

None.

Log in via your institution

Log in to Taylor & Francis Online

There are no offers available at the current time.

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.